Eli Lilly Zepbound Performance

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

The study revealed Zepbound users experienced an average waist reduction of 18.4 centimeters, versus 13 centimeters for those on Wegovy.

EconoTimes · 2d

· 2d

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

· 12d · on MSN

Zepbound Miss Hits Eli Lilly Shares: What’s Behind the Slump?

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

12don MSN

Eli Lilly’s Shares Sink on Investor Concerns About CVS Move

Eli Lilly & Co.’s shares dropped in morning trading after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound, making rival Wegovy more widely available.The drugmaker also cut its full-year earnings outlook,

12don MSN

Why Eli Lilly Stock Is Sinking Today

Shares of Eli Lilly ( LLY -5.50%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.77%) gained 1% and the Nasdaq Composite ( ^IXIC -0.87%) gained 1.9%.

Yahoo Finance2d

Eli Lilly and Company (LLY)

At 72 weeks, Zepbound met the primary endpoint and ... and media to further detail the company's financial performance. Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase ...

Morningstar13d

Eli Lilly Earnings: Solid Performance Overshadowed by Novo’s Obesity Coverage Win

Eli Lilly’s LLY first-quarter revenue grew 45%, as combined sales for Mounjaro (diabetes) and Zepbound (obesity ... future competitors means non-GAAP performance margin (similar to operating ...